FDA Rejects EPIX Appeal To Avoid New Trials

Law360, New York (August 28, 2006, 12:00 AM EDT) -- On Monday, the U.S. Food and Drug Administration denied an appeal from drug maker EPIX Pharmaceuticals Inc. to avoid a second round of trials for Vasovist, an injectible product already approved in Europe for use in magnetic resonance imaging (MRI).

The FDA’s Office of New Drugs suggested in a letter to EPIX that if the company decides to go forward with the additional clinical research, it should conduct two new clinical trials rather than rely on a blinded reread of previously submitted data.

EPIX, based in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.